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OBESITY AND MEDICARE EXPENDITURE: ACCOUNTING FOR AGE-
RELATED HEIGHT LOSS
Onwudiwe N1, Stuart B2, Zuckerman IH2, Sorkin J3
1University of Maryland School of Pharmacy, SILVER SPRING, MD, USA, 2University of 
Maryland School of Pharmacy, Baltimore, MD, USA, 3University of Maryland School of 
Medicine Division of Gerontology, Baltimore, MD, USA
OBJECTIVES: To determine the relationship between body mass index (BMI) and 
Medicare expenditure for adults 65-years and older and determine whether this rela-
tionship changes after accounting for possible misclassiﬁ cation associated with age-
related height loss. METHODS: Using a cross-sectional study design, the relationship
between BMI and Medicare expenditure was examined among beneﬁ ciaries who
completed the Medicare Current Beneﬁ ciary Survey (MCBS) in 2002, were not 
enrolled in Medicare HMO, had a self-reported height and weight, and were 65 and
older (n  7707). Subjects were classiﬁ ed as underweight, normal weight, overweight, 
obese (obese I), and severely obese (obese II/III). To adjust for the artifactual increase
in BMI, the reported height was transformed by adding the sex-speciﬁ c age-associated
height loss to the reported height in MCBS. The main outcome variable was total 
Medicare expenditure. RESULTS: There is a U-shaped association between BMI and 
Medicare expenditure: underweight $8238 (p  0.0005), normal weight $6801 (p 
0.0000), overweight $5653 (reference), obese I $6716 (p  0.0031) and obese II/III 
$7912 (p  0.0001), p values are compared to overweight. A U-shaped association 
was also seen after accounting for height loss: underweight $7878 (p  0.0003), 
normal weight $6308 (p  0.2465), overweight $5988 (reference), obese I $7350 (p 
 0.0031) and obese II/III $8171 (p  0.0029) compared to overweight. CONCLU-
SIONS: Previous research have looked at the relationship of BMI to health care costs 
and found that the full burden of medical expenditures is found in the overweight and 
obese categories. This study demonstrates that minimal cost is not normal BMI, but 
rather overweight, regardless of whether age-associated loss of height is accounted for. 
However, accounting for age-associated loss of height does decrease the magnitude of 
the spending difference between normal weight and overweight.
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ESTIMATION OF CLINICAL AND ECONOMIC IMPACT OF CHRONIC
PAIN ON THE BENEFICIARIES OF A PRIVATE HEALTH PLAN IN BRAZIL
Reis Neto JP, Stefani S
CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil
OBJECTIVES: There are no detailed assessments for Brazil regarding the prevalence
of chronic pain. The literature describes prevalence of 8% to 60%. The objective
of this study is to estimate the impact of this disease on a population of a private
health plan and the association with ﬁ nancial expenses. METHODS: An epidemiologi-
cal survey was performed on 46,407 beneﬁ ciaries (37.8% from the global life cover-
age), 4,700 of whom referred a variety of symptoms, including 1,469 (31%) with
pain complaints. Primary data, concerning expenses with hospitalization and use of 
medical services during a period of 12 months, of beneﬁ ciaries who referred pain, 
were analyzed and compared with those of individuals without this symptom. Data, 
based on a pharmacy beneﬁ t program, concerning 54,843 units of reimbursed medica-
tions, was collected to identify the most frequently drugs used for this symptom.
RESULTS: From the beneﬁ ciaries who mentioned pain, 30% were predominantly in
the lower limbs, 30% low back pain, 18% joints, 9% abdomen and 14% other kinds. 
The correlation between two groups demonstrated that patients who had chronic pain 
had a 2.6 higher use of physician and hospital services (clinic, exams and inpatient 
care) and an annual expenditure per capita of U$ 581.35 compared to $ 233.55 in 
the group without pain complaints (p  0.001). Among the most frequently reimbursed 
medications, 36% were products commonly used for pain relief: 10.5% non steroidal 
anti-inﬂ ammatory drugs, 9% antiepileptic, 7.3% non opioid; 4.4% ansiolytics, 3.8% 
antidepressant and 1% neuroleptic drugs. CONCLUSIONS: This epidemiological 
survey and the correlation with pharmacy beneﬁ t data, demonstrated a high preva-
lence of spontaneous pain complaints and a higher demand of the health insurance 
resources by those patients who mentioned this symptom spontaneously. The ﬁ ndings
of this study suggest the need implementing effective support measurements for
chronic pain patients.
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EVALUATING CLINICAL OUTCOMES OF AN EMPLOYER SPONSERED
MULTI CENTER DIABETES AND HYPERTENSION MEDICATION
THERAPY MANAGEMENT PROGRAM (MTMP)
Pinto SL, Bechtol R, Kumar J
University of Toledo, Toledo, OH, USA
OBJECTIVES: Eevaluate the clinical outcomes of a pharmacist-conducted MTMP for 
Lucas County employees and their dependents with diabetes and/or hypertension over 
a one year period. METHODS: A retrospective-prospective study using a cohort
receiving pharmacist provided MTM services in Northwest Ohio was used. Services
were provided to eligible Lucas County employees by a coalition of independent
pharmacies. Subjects eligible to participate must have had primary medical insurance
and prescription coverage through Lucas County and should have a diagnosis of dia-
betes and hypertension. Data was extracted from the pharmacists’ intake forms and
clinical notes. Clinical outcomes extracted were A1c, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), and body mass index (BMI). Patient’s self-monitored 
blood glucose (SMBG) and caffeine intake per day were also documented. The patients 
considered for analyses had at least two documented visits at one of the coalition
pharmacies within one year of their enrollment. Wilcoxon signed-rank test was used
to analyze data. RESULTS: A total of 467 patients have been enrolled to date. Of 
these, 193 patients have documented baseline A1c values. For A1c, patients with
values greater than 7 at baseline were considered for data analyses (N  70). Within 
one year of starting the MTM program, these patients’ mean A1c values decreased
from 8.21 to 7.41 (P  0.000). Three hundred and ﬁ fty three patients have documented 
baseline blood pressure values. Within 1 year, the SBP decreased from 130.72 to 
127.84 (P  0.006) and DBP decreased from 81.75 to 80.03 (P  0.004) (N  319). 
Similarly, BMI has decreased non-signiﬁ cantly, caffeine consumption has decreased
signiﬁ cantly (P  0.05) (N  143) and SMBG per day has also increased signiﬁ cantly
(P  0.05) (N  82). CONCLUSIONS: This study provides an initial glimpse into the 
impact of pharmacists’ interventions on clinical outcomes for patients participating in 
an employer-sponsored MTMP.
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UNDERSTANDING PATIENTS DIAGNOSED WITH ATHEROSCLEROSIS
AND THEIR DIAGNOSIS AND TREATMENT PATTERNS
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OBJECTIVES: To examine the characteristics of patients diagnosed with atheroscle-
rosis and describe the method of diagnosis and their management in a US managed
care setting. METHODS: Retrospective study utilizing administrative claims data from 
a US national health plan with 10 million commercial and Medicare Advantage 
members identiﬁ ed patients between March 31, 2005 and February 28, 2006, who 
were newly diagnosed with atherosclerosis (i.e., with no diagnosis of atherosclerosis 
and no history of cardiovascular events in the previous year). Patient demographics 
and Charlson comorbidity scores were computed. Lipid values and cardiac diagnostic 
tests were estimated one year pre- and post-diagnosis. RESULTS: A total of 58,060 
patients with newly diagnosed primary atherosclerosis were identiﬁ ed. The patient 
population was comprised of 60% men and 70% were 50 years of age. The mean 
Charlson comorbidity score was 2.0, with 25% of patients with diabetes, 15% with 
COPD, and 7% with congestive heart failure. Approximately, 55% of patients were
at high or moderate risk of coronary heart disease (CHD) based on National Choles-
terol Education Program Adult Treatment Panel III guidelines. The majority of patients
(45%) were managed by a cardiologist at the time of atherosclerosis diagnosis. Of 
patients with lipid value measures, mean LDL-C levels were 118 mg/dL pre-diagnosis
and 113 mg/dL post-diagnosis. Less than 20% of patients with atherosclerosis had
angiography, ultrasound or cardiac stress test within the year preceding diagnosis and 
12% of all patients were tested 3 months prior to diagnosis. CONCLUSIONS:
Patients diagnosed with atherosclerosis were older, had more comorbidities and were 
more likely to be male. They had a moderate or high CHD risk and the majority was 
managed by cardiologists. Future similar research should focus on identifying distin-
guishing characteristics to facilitate identiﬁ cation of patients with atherosclerosis by 
health care providers.
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MEDIATING ROLE OF CEREBROVASCULAR DISEASE IN THE 
ASSOCIATION BETWEEN DIABETES MELLITUS AND DEMENTIA
Lu Z, Stuart B, Zuckerman IH
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: Diabetes mellitus (DM) has been reported to affect cognition, but its 
relationship with dementia remains uncertain. The literature also indicates that DM
is a major risk factor for cerebrovascular disease (CVD), a disorder that signiﬁ cantly 
increases dementia risk, suggesting that the association between DM and dementia
might be mediated through CVD, although quantitative analysis on its role is lacking.
Thus, we 1) estimated the association between DM and dementia among the elderly,
and 2) determined the mediating role of CVD in that association. METHODS: A ret-
rospective cross-sectional study was conducted using the 2002 Medicare Current 
Beneﬁ ciary Survey. Participants were 8132 community-dwelling and institutionalized 
fee-for-service Medicare beneﬁ ciaries aged 65 years. The dependent variable was a
diagnosis of dementia (Alzheimer’s disease, vascular dementia, or either type); the 
independent variable of interest was presence of DM during 2002. Potential confound-
ers were age, gender, race, education, income and smoking status. Medicare claims 
ﬁ les from 2002 were used to identify the dependent and independent variables. Kappa 
values of measuring DM and dementia between claims based and self/proxy-reported 
diseases were also addressed to evaluate possible misclassiﬁ cation bias. Three multi-
variable logistic regression models were used to estimate the association between 
dementia and DM. We estimated models with and without CVD to determine the 
mediating effect of CVD. RESULTS: Patients with DM were 36–63% more likely to 
have a dementia diagnosis (Alzheimer’s disease OR  1.36, 95% CI 1.03–1.78; vas-
cular dementia OR  1.56, 95% CI 1.27–1.92; overall OR  1.63, 95% CI 1.35–1.97).
After adding CVD to the models, DM was still signiﬁ cantly associated with dementia
of all types and vascular dementia, but not with Alzheimer’s disease. CONCLUSIONS:
Patients with DM are more likely to suffer from dementia and the association is only 
partially mediated through CVD.
